Verseon Corp. presented the latest preclinical results on its anti-coagulant drug family at the BioEurope Spring 2016 conference in Stockholm, Sweden, last week.
The direct thrombin inhibitors (DTIs) are a promising treatment for venous thrombotic disorders.
The highly selective, small molecule DTIs provide anti-coagulant action while reducing the bleeding risk that patients face when prescribed the current drugs used for preventing blood clots and other thrombotic disorders. Among the potential uses of Verseon's DTIs are stroke prevention and preventing blood clots in deep vein thrombosis.
Verseon Corp. has been developing its proprietary drug discovery platform for 10 years. The platform allows the company to discover novel drug solutions using computers to model molecular interactions and integrate the chemistry of synthetic and medicinal drug-like compounds.
Previously, locating potential drugs was a trial and error process. By designing a family of potential drug candidates, Verseon's platform provides multiple choices for testing in clinical trials. Each candidate has its own recipe, increasing the potential that one or more of the drug chemotypes will produce an effective therapy.
Verseon is currently working on solutions for anticoagulants, diabetic macular edema and solid tumor cancers.